74th Day Of Lockdown

Maharashtra80229286942849 Tamil Nadu2869415762235 Delhi2633410315708 Gujarat19119130111190 Rajasthan100847359218 Uttar Pradesh97335648257 Madhya Pradesh89965878384 West Bengal73032912366 Karnataka4835169357 Bihar4598223329 Andhra Pradesh4250256573 Haryana3597120924 Telangana32901627113 Jammu and Kashmir3142104835 Odisha247814819 Punjab2415204347 Assam19894434 Kerala170071215 Uttarakhand115328610 Jharkhand7642975 Chhatisgarh6781892 Tripura6221730 Himachal Pradesh3691636 Chandigarh3022225 Goa126570 Manipur124110 Puducherry90330 Nagaland8000 Arunachal Pradesh3710 Meghalaya33131 Mizoram1710 Sikkim200
Business Companies 14 Jul 2019 Lupin aims to launch ...

Lupin aims to launch new products across geographies this fiscal

PTI
Published Jul 14, 2019, 8:23 pm IST
Updated Jul 14, 2019, 8:26 pm IST
Lupin said it launched 22 new products in the US market last fiscal.
Addressing shareholders in the company's Annual Report for 2018-19, Lupin Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta said the new launches across the globe would help it achieve sustainable growth. (Photo: Representational)
 Addressing shareholders in the company's Annual Report for 2018-19, Lupin Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta said the new launches across the globe would help it achieve sustainable growth. (Photo: Representational)

New Delhi: Pharmaceutical maker Lupin aims to launch its first biosimilar product and commercialise its first inhalation product in the US in the current fiscal.

Addressing shareholders in the company's Annual Report for 2018-19, Lupin Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta said the new launches across the globe would help it achieve sustainable growth.

 

"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market, commercialise our first inhalation product in the US, continue the growth momentum in our US generics business and launch our injectables portfolio," they said in a joint letter to the shareholders.

Coupling this with the building of Solosec brand in the US, NaMuscla in Europe and Bipresso in Japan will help the company drive sustainable growth, they added.

"Creating a growth business while making a difference, has been our ambition. We are committed to building a promising future. We will deliver this by executing on our well-defined strategic priorities, investing in capabilities and manufacturing excellence to support operations that meet the highest standards," the company's leadership said.

The firm's first biosimilar Etanercept is approved for launch in Japan, while the European approval is awaited, the report said.

Lupin said it launched 22 new products in the US market last fiscal.

"With over 157 abbreviated new drug applications (ANDAs) currently pending approval with the USFDA, we have a rich pipeline addressing a total market size of over USD 52 billion," the letter said.

Lupin added that while there were many successes throughout the course of the last financial year, the company also faced many challenges on the compliance front.

"We had our share of challenges, particularly, on the compliance front. We have made significant progress on our remediation and enhancement plan and are committed to sustainable compliance throughout all our sites. As an organisation this is one of our biggest priorities," the letter said.

The Mumbai-based company's various manufacturing plants have come under the US Food and Drug Adminstration's (USFDA) scanner for various compliance issues.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT